AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen
MarketWatchAbbVie Inc.’s stock fell 0.5% early Monday, after the biotech lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen.